Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4653445 | 0.87 | ADORA3 (0.71) | HIF1AADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL30601880 | 0.86 | ADORA2A (0.66) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL21418866 | 0.86 | ADORA2A (0.66) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL29100475 | 0.86 | ADORA2A (0.66) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL8624075 | 0.86 | ADORA2A (0.66) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL30601881 | 0.86 | ADORA2A (0.66) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL8624065 | 0.86 | ADORA2A (0.66) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL5963084 | 0.84 | ADORA2A (0.67) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5963203 | 0.84 | ADORA2A (0.67) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL24359132 | 0.84 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5856466-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-05 | — | — | US | claimed |
| US-5646265-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMCEUTICALS, INC. (US) | 1997-07-08 | — | — | US | claimed |
| EP-0651759-A4 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF. | ISIS PHARMACEUTICALS INC (US) | 1995-10-25 | — | — | EP | claimed |
| EP-0651759-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-10 | — | — | EP | claimed |
| WO-1994002501-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-02-03 | — | — | WO | claimed |
| US-20250084409-A1 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | VERVE THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| EP-4486355-A2 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | Verve Therapeutics, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-119137271-A | Compositions and methods for capping RNA | 维乎医疗有限公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2023167880-A2 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | VERVE THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-1223173-A2 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS, INC. (US) | 2002-07-17 | — | — | EP | disclosed |
| US-6242592-B1 | Process for the preparation of 2′-O-alkyl-guanosine, cytidine, and uridine phosphoramidites | ISIS PHARMACEUTICALS, INC. | 2001-06-05 | — | — | US | disclosed |
| US-6133438-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-5914396-A | 2'-O-modified nucleosides and phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-06-22 | — | — | US | disclosed |
| US-5856466-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5646265-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMCEUTICALS, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0651759-A4 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF. | ISIS PHARMACEUTICALS INC (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0651759-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002501-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084409-A1 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | RNGTT, NSUN2, RNMT | LMNA 500/4885NT5E 138/4885HIF1A 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.